The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
📻 Siste episoder av ACE OncoCast
Her er de nyeste episodene tilgjengelige via RSS-feeden:
Expert Interview of Dr Enrique Grande: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer (00:20:09)
Enrique Grande, MD, MSc, PhD Quirónsalud Madrid Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/...
Expert Interview of Dr Real: Molecular Pathology and Biology of Urothelial Cancer (00:11:28)
Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the additio...
Expert Interview of Dr Guerrero: Optimal Management for NMIBC and MIBC Patients from a Surgical Perspective (00:16:54)
Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addit...
Expert Interview of Dr Carballo: The Role of Radiotherapy for MIBC Patients (00:05:25)
Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD...
Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (1 of 2) (00:12:33)
Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition ...
Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2) (00:04:10)
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/P...
Expert Interview of Specialist Insights in Urothelial Cancer: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer (00:24:54)
Enrique Grande, MD, MSc, PhD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition ...
Expert Interview of Specialist Insights in Urothelial Cancer: Molecular Pathology and Biology of Urothelial Cancer (00:15:17)
Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of ...
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 3 (00:21:33)
Episode 3: Panel Discussion & Pearls for Practice Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the...
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 2 (00:20:58)
Episode 2: Case 1: Second-line and salvage treatment options after maintenance immunotherapy Case 2: Second-line and salvage treatment options after platinum-based chemotherapy Kate Smith, MBBS, MRC...
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 1 (00:21:41)
Episode 1: Opening & Keynote Speech: Second-line and salvage treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Philippe Barthélémy, MD, PhD The ...
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 3 (00:22:41)
Episode 3: Panel Discussion & Pearls for Practice Fernando Maluf, MD, PhD, Enrique Grande, MD, MSc, PhD and Joachim Chan, BSc, MBBS, MRCP, FRCR, MD The therapeutic landscape of unresectable locally ...
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 2 (00:23:41)
Episode 2: Case 1: First-line treatment with maintenance immunotherapy for a platinum-eligible patient Case 2: First-line treatment with mono-immunotherapy for a cisplatin-ineligible patient Joachim...
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 1 (00:26:44)
Episode 1: Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Enrique Grande, MD, MSc, PhD The therapeutic l...
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 4: Novel Drugs in Development (00:24:53)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel anti...
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 3: Second/subsequential Treatment Decision-making (00:16:43)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel anti...
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 1: First-line Treatment Decision-making (00:14:25)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel anti...
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 2: First-line Maintenance Treatment Decision-making (00:20:43)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel anti...
Expert Interview: Frequently Asked Questions (FAQs) for Second Line (2L) and Salvage Treatments (00:10:50)
There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. I...
Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC) (00:13:53)
Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a spe...
Expert Interview: Frequently Asked Questions (FAQs) for Non Muscle Invasive Bladder Cancer (NMIBC) (00:07:22)
About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose in...
Expert Interview: Frequently Asked Questions (FAQs) for First Line (1L) Treatment Decision making (00:17:07)
Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving...
Personalized therapy in SCLC: Promises and challenges (00:09:52)
In the third and final podcast on extensive-stage SCLC, the experts discuss ongoing trials, as well as potential predictive biomarkers of response, and the problem of tumor plasticity.
Closer look at the biology of SCLC and molecular subtypes (00:10:58)
In the second podcast on extensive-stage SCLC, the experts examine the biology of SCLC and discuss the molecular subtypes, which have distinct therapeutic vulnerabilities.
Current standard of care for ES SCLC (00:16:43)
In this first of three podcasts on extensive-stage SCLC, the experts discuss the management of patients with relapsed SCLC based on current evidence and guidelines.
Side 1 av 1
ACE OncoCast - Gratis RSS Feed for Norsk Podcast | OpenPodMe | OpenPodMe - Åpen RSS for Norske Podcaster
